{'fraction_non_alphanumeric': 0.03247373447946514, 'fraction_numerical': 0.015281757402101241, 'mean_word_length': 5.849673202614379, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Efficacy Of Gonadotropin‐Releasing Hormone Agonist (Buserelin) in The Treatment Of Endometriosis

In a multi center study, the efficacy of and tolerance of 6 months' intranasal gonadotropin‐releasing hormone agonist (buserelin) treatment (300 μg × 3/day) on laparoscopically verified endometriosis was evaluated in 25 patients. At second‐look laparoscopy at the end of medication, the mean endometriosis score had fallen by 82.2%. All endometriosis‐associated symptoms and physical findings decreased or almost disappeared during buserelin administration. After discontinuing therapy, they showed a tendency to reappear, but nevertheless they were milder after one year of follow‐up, than before treatment. Seven (54%) of the 13 women wishing pregnancy actually conceived. Vaginal irregular spotting bleedings during the first 2 months occurred in 7 patients. No patient withdrew from the trial because of side effects, although almost all women developed symptoms of estrogen deficiency (serum estradiol concentrations fell to menopausal levels).